To identify early molecular changes induced by dual HER2 blockade in patients with HER2-E disease, gene expression profiling was performed in 96 tumor samples obtained before and at day 14 of treatment with lapatinib and trastuzumab (and endocrine therapy if the tumor was HR+) in the PAMELA phase II clinical trial7. This evidence concerns the gene ERBB2 and neoplasm.